Estados Unidos · Bolsa y Finanzas · The Motley Fool

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Publicado por The Motley Fool · Estados Unidos hace 11 h

Viking Therapeutics tested various doses of its leading anti-obesity candidate, VK2735, administered subcutaneously every other week or monthly (VK2735 also mimics the action of…

Leer el artículo completo en The Motley Fool Inicie sesión para guardar

MediaNews muestra el titular y el resumen publicados por el medio. El artículo completo se lee en el sitio del editor. (www.fool.com)

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

También te puede interesar

MetaMask exits Lido validators as it investigates security incident

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.

Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.

Compartir

También te puede interesar

MetaMask exits Lido validators as it investigates security incident

Read the letter Trump is sending along with $500 checks to nearly 1 million Americans for ACA 'refunds'

Iran’s Disappearing Oil Is Becoming Everyone’s Problem

Google releases Gemini 4 Argon, called its most powerful model yet

Transocean gets DOJ approval for Valaris acquisition

Bessent Settled Tax Issue That Had Put Him at Odds With I.R.S.